Phillips Medisize: Combines Drug Delivery Platform and Strategic CDMO Expertise

As pharmaceutical companies advance increasingly sophisticated therapeutic modalities, the demand for reliable drug delivery products has never been greater. Phillips Medisize established itself as a trusted drug delivery platform provider and contract development and manufacturing organization (CDMO), helping pharmaceutical and biotechnology companies move from concept to commercialization through integrated device development, engineering and manufacturing solutions. 

Leveraging more than 60 years of experience, we support a broad spectrum of injectable, inhalation and specialty therapeutic programs. Our company works closely with customers throughout every stage of development, from discovery to large-scale commercial manufacturing, providing expertise designed to help reduce complexity, manage risk and accelerate time to market. 

At the core of our pharmaceutical offering is a combination of customized drug delivery development services and proven platform technologies. We provide device design and engineering, design for manufacturing strategy, engineering, cGMP manufacturing, unified quality system, and regulatory support for organizations seeking efficient pathways to commercialize combination products and drug-device solutions. Our platform approach enables pharmaceutical companies to leverage established technologies to help shorten development cycles.

Envoi™ Pen Injector stands out as scalable injectable platform designed around evolving patient and market needs. The Envoi Pen Injector provides a familiar, user-friendly platform for therapies including insulin and GLP-1 medications. Envoi™ is designed to help pharmaceutical companies accelerate their therapeutic launches. Supported by extensive manufacturing expertise and technical documentation, the platform helps simplify commercialization efforts while maintaining a strong focus on patient-centric usability and reliability. 

We expanded our capabilities in inhalation therapies with a portfolio of dry powder inhaler (DPI) platforms derived from commercially validated technologies, along with the FOX™ Vibrating Mesh Nebulizer. Our FOX™ platform is a breath-activated system capable of delivering therapeutic treatment efficiently. 

Our inhalation expertise is further strengthened with our inhaled drug formulation development offering. Our formulation scientists work with small molecules, biologics, complex combination products and generics to ensure the therapy to suitable for any inhaled product technologies. This expanded expertise enables us to provide an integrated development pathway that combines formulation knowledge, device engineering, pharmaceutical analysis, clinical-trial supply and commercial manufacturing support. 

For pharmaceutical leaders seeking to collaborate, we offer both innovation and scale. We have a unique combination of global manufacturing capabilities, engineering excellence, platform-based development strategies and patient-focused device design. The result is a comprehensive pharmaceutical solutions portfolio designed to help companies bring life-enhancing and lifesaving therapies to patients faster, more efficiently and with greater confidence.